C-telopeptide pyridinoline crosslinks of type i collagen, soluble RANKL, and osteoprotegerin levels in crevicular fluid of dental implants with peri-implantitis: A case-control study

International Journal of Oral and Maxillofacial Implants

Volumn 26, Issue 2, 2011, Pages 282-289

  Arıkan, Fatih ^a   Buduneli, Nurcan ^a   Lappin, David F ^b  

^a EGE UNIVERSITY   (Turkey)

^b GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

Author keywords

C telopeptide pyridinoline crosslinks of type i collagen; Crevicular fluid; Endosseous dental implants; Osteoprotegerin; Peri implant peri implantitis; Soluble receptor activator of nuclear factor kappa B ligand

Indexed keywords

ALBUMINOID; BIOLOGICAL MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PEPTIDE; TNFSF11 PROTEIN, HUMAN;

ALVEOLAR BONE LOSS; ARTICLE; CASE CONTROL STUDY; CHEMISTRY; CLASSIFICATION; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; GINGIVA BLEEDING; GINGIVITIS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PERIIMPLANTITIS; PERIODONTAL POCKET; PERIODONTICS; TIME; TOOTH IMPLANTATION; TOOTH PLAQUE;

ALBUMINS; ALVEOLAR BONE LOSS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLLAGEN TYPE I; CROSS-SECTIONAL STUDIES; DENTAL IMPLANTS; DENTAL PLAQUE INDEX; FEMALE; GINGIVAL CREVICULAR FLUID; GINGIVAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PEPTIDES; PERI-IMPLANTITIS; PERIODONTAL INDEX; PERIODONTAL POCKET; RANK LIGAND; TIME FACTORS;

EID: 80054816409     PISSN: 08822786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Aglietta M, Siciliano VI, Zwahlen M, et al. A systematic review of the survival and complication rates of implant-supported fixed dental prostheses with cantilever extensions after an observation period of at least 5 years. Clin Oral Implants Res 2009; 20: 441-451.
2. Pjetursson BE, Tan K, Lang NP, Bragger U, Egger M, Zwahlen M. A systematic review of the survival and complication rates of fixed partial dentures (FPDs) after an observation period of at least 5 years. Clin Oral Implants Res 2004; 15: 625-642.
3. DeSmet E, Van Steenberghe D, Quirynen M, Naert I. The influence of plaque and/or excessive loading on marginal soft and hard tissue reactions around Brånemark implants:A review of literature and experience. Int J Periodontics Restorative Dent 2001; 21: 381-393.
4. Mombelli A, Van Oosten MA, Schurch E Jr, Lang NP. The microbiota associated with successful or failing osseointegrated titanium implants. Oral Microbiol Immunol 1987; 2: 145-151.
5. Tonetti M, Schmid J. Pathogenesis of implant failures. Periodontol 2000 1994; 4: 127-138.
6. Giannobile WV. C-telopeptide pyridinoline cross-links. Sensitive indicators of periodontal tissue destruction. Ann N Y Acad Sci 1999; 878: 404-412.
7. Seibel MJ. Biochemical markers of bone metabolism in the assessment of osteoporosis: Useful or not? J Endocrinol Investig 2003; 26: 464-471.
8. Narayanan AS, Page RC. Connective tissues of the periodontium:A summary of current work. Coll Rel Res 1983; 3: 33-64.
9. Oringer RJ, Al-Shammari KF, Aldredge WA, et al. Effect of locally delivered minocycline microspheres on markers of bone resorption. J Periodontol 2002: 73: 835-842.
10. Oringer RJ, Palys MD, Iranmanesh A, et al. C-telopeptide pyridinoline cross-links (ICTP) and periodontal pathogens associated with endosseous oral implants. Clin Oral Implants Res 1998; 9: 365-373.
11. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumour necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-357.
12. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclast inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-3602.
13. Quinn JMW, Horwood NJ, Elliott J, Gillespie MT, Martin TJ. Fibroblastic stromal cells express receptor activator of NFkappa B ligand and support osteoclast differentiation. J Bone Miner Res 2000; 15: 1459-1466.
14. Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kappa B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthr Rheum 2000; 43: 259-269.
15. Horwood NJ, Kartsogiannis V, Quinn JMW, Romas E, Martin TJ, Gillespie MT. Activated T lymphoctes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999; 265: 144-150.
16. Kotake S, Udagawa N, Hakoda M, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes:Possible role of T cells in bone destruction in rheumatoid arthritis patients. Arth Rheum 2001; 44: 1003-1012.
17. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96: 3540-3545.
18. Lacey DL, Timms E, Tan H-L, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176.
19. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis. Nature 1999; 397: 315-323.
20. Kanzaki H, Chiba M, Yoshinobu S, Mitani H. Periodontal ligament cells under mechanical stress induce osteoclastogenesis by receptor activator of nuclear factor κB ligand up-regulation via prostaglandin E2 synthesis. J Bone Miner Res 2002; 17: 210-220.
21. Sakata M, Shiba H, Komatsuzawa H, et al. Expression of osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human dental mesenchymal cells and epithelial cells. J Bone Miner Res 1999; 14: 1486-1492.
22. Jin Q, Cirelli JA, Park CH, et al. RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis. J Periodontol 2007; 78: 1300-1308.
23. Bostancı N, Ilgenli T, Emingil G, et al. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: Implications of their relative ratio. J Clin Periodontol 2007; 34: 370-376.
24. Lu H-K, Chen Y-L, Chang H-C, Li C-L, Kuo My-P. Identification of the osteoprotegerin/receptor activator of nuclear factorkappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. J Periodontal Res 2006; 41: 354-360.
25. Mogi M, Otogoto J, Ota N, Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res 2004; 83: 166-169.
26. Vernal R, Chaparro A, Graumann R, Puente J, Valenzuela MA, Gamonal J. Levels of cytokine receptor activator of nuclear factor κB ligand in gingival crevicular fluid in untreated chronic periodontitis patients. J Periodontol 2004; 75: 1586-1591.
27. Ramseier CA, Kinney JS, Herr AE, et al. Identification of pathogen and host-response markers correlated with periodontal disease. J Periodontol 2009; 80: 436-446.
28. Frodge BD, Ebersole JL, Kryscio RJ, Thomas MV, Miller CS. Bone remodelling biomarkers of periodontal disease in saliva. J Periodontol 2008; 79: 1913-1919.
29. Monov G, Strbac GD, Baron M, Kandler B, Watzek G, Gruber R. Soluble RANKL in crevicular fluid of dental implants: A pilot study. Clin Implant Dent Relat Res 2006; 8: 135-141.
30. Arıkan F, Buduneli N, Kütükçüler N. Osteoprotegerin levels in peri-implant crevicular fluid. Clin Oral Implants Res 2008; 19: 283-288.
31. Silness J, Löe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 1964; 22: 121-135.
32. Adonogianaki E, Moony J, Wennström JL, Lekholm U, Kinane DF. Acute-phase proteins and immunoglobulin G against Porphyromonas gingivalis in peri-implant crevicular fluid:A comparison with gingival crevicular fluid. Clin Oral Implants Res 1995; 6: 14-23.
33. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65-70.
34. Lappin DF, Sherrabeh S, Jenkins WM, Macpherson LM. Effect of smoking on serum RANKL and OPG in sex, age and clinically matched supportive-therapy periodontitis patients. J Clin Periodontol 2007; 34: 271-277.
35. Tümer C, Aksoy Y, Güncü GN, Nohutçu RM, Kılınç K, Tözüm TF. Possible impact of inflammatory status on C-telopeptide pyridinoline cross-links of type I collagen and osteocalcin levels around oral implants with peri-implantitis: A controlled clinical trial. J Oral Rehabil 2008; 35: 934-939.
36. Nakashima T, Kobayashi Y, Yamasaki S, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Com 2000; 275: 768-775.
37. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: A review. Crit Rev Oral Biol Med 1993; 4: 197-250.
38. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin:A novel-secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
39. Teng YT, Nguyen H, Gao X, et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000; 106: 59-67.
40. Crotti T, Smith MD, Hirsch R, et al. Receptor activator NF κB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 2003; 38: 380-387.